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Introduction
Type 2 diabetes is a significant cause of morbidity and 
mortality among Aboriginal Australians. Aboriginal people
suffer between 12 to 17 times more deaths due to type 2 
diabetes than non-Indigenous Australians, while overall
prevalence rates are within the range of 10-30% and at least 
two to four times that of the non-Aboriginal population.
1,2
Studies such as the Diabetes Control and Complications Trial
(DCCT) and the United Kingdom Prospective Diabetes
Study (UKPDS) have confirmed that good control of diabetes
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Abstract
This study describes the development, implementation and management of a multi-faceted quality assurance program called
Quality Assurance for Aboriginal Medical Services (QAAMS) to support point-of-care HbA1c  testing on the Bayer DCA 2000
in Aboriginal people with diabetes from 45 Australian Aboriginal Community Controlled Health Services. 
The quality assurance program comprised four elements: production of culturally appropriate education resources, formal 
training for Aboriginal Health Workers conducting HbA1c testing, an external quality assurance program and on-going quality
management support services including a help hotline and an annual workshop. Aboriginal Health Workers were required to
test two quality assurance (QAAMS) samples in a blind sense every month since July 1999. Samples were linearly related and
comprised six paired levels of HbA1c. The short and long term performance of each service’s DCA 2000 was reviewed 
monthly and at the end of each six month testing cycle. 
The average participation rate over 7 six-monthly QAAMS testing cycles was 88%. 84% of 3100 quality assurance tests 
performed were within preset limits of acceptability. The median precision (CV%) for HbA1c  testing has averaged 3.8% across
the past 5 cycles (range 3.4 to 4.0%) and is continuing to improve.  The introduction of a medical rebate for HbA1c  testing has
ensured the program’s sustainability.
Through continuing education and training, Aboriginal Health Workers have achieved consistent analytical performance for
HbA1c  testing on the DCA 2000, equivalent to that of laboratory scientists using the same instrument. This unique quality 
assurance model can be readily adapted to other Indigenous health settings and other point-of-care tests and instruments.
(Clin Biochem Rev 2003; 24:124-31)
is critical to prevent the long-term debilitating complications
of this disease such as nephropathy, neuropathy and 
retinopathy.
3,4
Haemoglobin A1c  (HbA1c) is a well-established
biochemical marker of diabetes control and can be 
conveniently measured on the small, portable DCA 2000
point-of-care analyser (Bayer Diagnostics, Melbourne,
Australia).
In 1998, the National Diabetes Strategy and Implementation
Plan, Australia recommended that a trial of the DCA 2000 for
HbA1c testing be conducted in Aboriginal primary health care
services.
5
The DCA 2000 was considered to have particular
application in the Aboriginal health care setting, notably in
rural and remote locations, where access to basic health care
is often limited and services may be several hundred 
kilometres from the nearest hospital laboratory.
6
In June 1999 the Australian Government’s Department of
Health and Ageing, through its Office for Aboriginal and
Torres Strait Islander Health (OATSIH) and in partnership
with the National Aboriginal Community Controlled Health
Organisation (NACCHO), commenced a pilot program for
on-site HbA1c testing using the DCA 2000. Forty-five
Aboriginal Community Controlled Health Services
(ACCHS) around Australia participated in the pilot.
Aboriginal Health Workers (Aboriginal people trained in 
primary health care and living in the community setting) 
performed the testing on behalf of their local or visiting 
medical officer. Testing was only conducted on Aboriginal
people with known diabetes, with a maximum of four HbA1c
tests being performed annually on each person. An HbA1c of
7% was considered the target for good control of diabetes in
Aboriginal people.
6
As a requirement of the pilot, the Department of Health and
Ageing determined that an on-going surveillance mechanism
was needed to ensure point-of-care HbA1c results generated in
the field were acceptable for patient care. As a result, the
RCPA Quality Assurance Programs Pty Ltd was initially 
contracted by the Department of Health and Ageing to 
develop, implement and manage a multi-faceted quality
assurance program to support HbA1c testing by Aboriginal
Health Workers. (The RCPA Quality Assurance Programs Pty
Ltd provides quality assurance programs to laboratories in
Australasia in collaboration with the Royal College of
Pathologists of Australasia and the Australasian Association
of Clinical Biochemists). The Department of Health and
Ageing (through its Diagnostics and Technology Branch)
have subsequently extended this contract to the end of 2005
and the program has now been integrated into mainstream
Aboriginal health care.
The quality assurance program developed by our group is
believed to be the first of its type for Indigenous people 
anywhere in the world. We describe the novel aspects of this
program, present the scientific results obtained over its first
three and a half years of operation, and comment on the
potential of this model to assist chronic disease prevention
and management in other Indigenous countries and 
communities.
Research Design and Methods
Bayer DCA 2000 Instrument 
The DCA 2000 point-of-care analyser is small (25cm high by
21cm wide by 25cm deep) and portable (weighing 5 kg).
Only one microlitre of whole blood (capillary or venous) is
required for the test, with the result available in 6 minutes.
The DCA 2000 determines both the concentrations of HbA1c
and total haemoglobin, with the ratio being expressed as the
percentage HbA1c. HbA1c is measured immunochemically by
a method based on inhibition of latex agglutination. Total
haemoglobin is measured spectrophotometrically following
its oxidation to methaemoglobin by potassium ferrocyanide
and the subsequent complexing of methaemoglobin with
thiocyanate to form thiocyan-methaemoglobin.
7
Participation
Forty-five Aboriginal Community Controlled Health
Services formed the initial intake of program participants
(Figure 1). Every State and Territory of Australia was 
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Figure 1. Location of Aboriginal Community Controlled
Health Services participating in the QAAMS program 
during 2002.
represented and the location of participants encompassed a
broad spectrum of urban, rural and remote Australia. There
have been minor changes to the mix of participants over the
past three and a half years due to changing health service 
priorities and/or Aboriginal Health Worker staff resources.
Fifty sites were enrolled in the program at the beginning of
2003. 
Quality Assurance Program
The quality assurance program to support HbA1c testing in the
Aboriginal community was called QAAMS (Quality
Assurance for Aboriginal Medical Services). As tests were
being conducted using a point-of-care medical instrument in
the community setting by Aboriginal Health Workers, the
design of the program needed to be broader and more 
intensive in its focus than a conventional laboratory-
based quality assurance program. Four key elements, namely
education, training, quality assurance, and on-going 
management support services for communities, formed the
cornerstone of the QAAMS program.
Education
A culturally appropriate set of education resources was 
developed in conjunction with senior Aboriginal health 
representatives, Aboriginal Health Workers, diabetes 
specialists and scientists. The resources comprised a 
laminated book, video and a series of posters. Topics covered
included diabetes and its complications, the importance of
controlling diabetes, the HbA1c test, the DCA 2000 machine
and the principles and practice of quality control and quality
assurance. The posters included step-by-step guides on how
to perform the HbA1c test on the DCA 2000 and how to 
conduct quality assurance testing on the DCA 2000. 
Training
Formal training sessions for 84 Aboriginal Health Workers
(and other allied health professionals) from every 
participating site were held at eight regional centres around
Australia over an eight week period from May to July 1999.
Training focussed on hands-on practical instruction in how to
use the DCA 2000 machine, perform the HbA1c test, and 
conduct quality assurance testing. Each service also received
their education resource kit at the training session. Once back
in the community, these resources were used as a refresher
course, to train other Aboriginal Health Workers, or for 
general community education about diabetes.
Quality Assurance
A quality assurance program commenced in July 1999 to
monitor the performance of DCA 2000 machines across all
participating sites. Since that time, 7 six-monthly testing
cycles have been completed to the end of 2002.
At the beginning of each year, all participants were sent a
package containing the materials needed to conduct their
QAAMS testing. The package included a testing kit 
containing 24 lyophilised QAAMS samples, each numbered
and dated, vials of water for reconstitution of those samples,
an information sheet, testing schedule and result sheets. An
international Reference Laboratory for Glycohaemoglobin
produced the samples for the program. The samples 
comprised paired and linearly related levels of HbA1c across
a range of concentrations from 5 to 14%. Services were
required to test two QAAMS samples per month, according
to the defined testing schedule that comprised two 
six-monthly testing cycles per year.  Testing could be 
performed at any time during the month that was convenient
to the service, provided the results were received at the
QAAMS reporting office by fax or post by the last day of
each month.  To ensure confidentiality of results, each 
service was allocated a specific community code number that
was stamped on their result sheets and all other printed 
matter. 
Within a week after the closing date for return of results for
each month, the QAAMS reporting office sent a graphical
report to each individual service (Figure 2). The report 
compared the results returned by that service with the pre-set
target values for each sample and with the range of results
from all other services. In addition, the report displayed
graphs that documented all previous results returned by the
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Figure 2. Example of the monthly summary report sent to all
QAAMS participants.
Footnote to Figure. For Cycles 1 and 2, the 
international reference laboratory set target values. For
Cycles 3 to 7, the median of all results submitted was used
as the target.  
service for that particular testing cycle. Through this method
of reporting, each service received regular monthly 
information on the short and long term performance of their
DCA 2000 machine. 
At the end of each cycle, summary analysis of six months of
data (12 specimens) was used to comment on each individual
site’s precision and accuracy. This data was used to identify
individual services that were experiencing significant 
analytical problems. Services were contacted and an action
plan implemented to redress poor performance.  
Other Management Services
A help hotline telephone service was established whereby
Aboriginal Health Workers could phone the QAAMS office
immediately a problem arose, particularly in relation to
instrument breakdown or other technical problems and 
interpretation of quality assurance results. A regular 
newsletter was also sent to all participants to update them on
current issues. Workshops for participants were held in
November 2001 and September 2002 and have now become
an annual feature on the program’s calendar. The workshop
provides Aboriginal Health Workers with opportunities for
retraining, networking, interactive discussion on all aspects
of the program and presentations from participants on how
their service is using the program. Representatives from the
Department of Health and Ageing and Bayer Australia also
attend the workshop. In addition to external quality assurance
assessment, the QAAMS program also monitored internal
quality control testing conducted by services using kits 
provided by the manufacturer (Bayer Normal and Abnormal




An overall participation rate of 88% (range 81% to 93%) has
been maintained across the first three and a half years (7 test-
ing cycles) of the program. This represents the return of 3100
QAAMS results from a possible 3524. On average, 81% of
participating services returned between 10 and a maximum of
12 results each cycle. 
Performance Indicators
Across three and a half years of testing, the percentage of
returned results that were within preset limits for 
acceptability was 84% (range 81% to 86%) (Table 1). This
represents 2590 acceptable results from 3100 results
returned. The limits of acceptability, called allowable limits
of performance, were set by the QAAMS program organisers
at ±0.5 up to an HbA1c of 10% and ±5% at HbA1c ≥10%.
These are the same limits used for the parallel
Glycohaemoglobin Quality Assurance Program run by the
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Table 1.  Key performance indicators in the QAAMS Program, 1999 - 2002
RCPA Quality Assurance Program Pty Ltd for laboratories in
Australasia and other parts of the world.
As stated earlier, the 12 samples in each cycle comprised six
paired levels of HbA1c concentration that were tested in 
random order pre-determined by the program organisers. 
The use of paired and linearly related samples for QAAMS
testing also enabled a direct measure of the precision and
accuracy across time of both individual DCA 2000 machines
and the group as a whole. The median coefficients of 
variation (CV%) and bias achieved by services participating
in the program is shown for each testing cycle in Table 1. The
median precision (CV%) for HbA1c testing has averaged
3.8% across the past 5 testing cycles, with 3.4% being
recorded for the most recent testing cycle. Notably the 
precision achieved by QAAMS participants has been 
steadily improving since the program began. 
How does this level of performance compare to laboratories
using the DCA 2000? The RCPA Quality Assurance
Programs also runs a laboratory-based Glycohaemoglobin
Quality Assurance Program, which uses the same material as
that for the QAAMS program. There are approximately 75
DCA 2000 laboratory users in this program. The comparative
analytical precision (median CV%) recorded for the QAAMS
and the laboratory-based Glycohaemoglobin programs since
the QAAMS program began shows that, for the past four 
testing cycles in particular, Aboriginal Health Workers
achieved an analytical performance equivalent to that of
trained laboratory scientists and technicians (Figure 3).
How does this performance compare to international 
consensus criteria on desirable performance standards for
HbA1c analysis?  The importance of imprecision as a key
component of HbA1c analysis is being increasingly 
recognised by the medical and scientific community 
world-wide. Based on clinical need from studies like the
UKPDS and DCCT and recent recommendations from key
professional bodies, there is now widespread international
consensus that the desirable precision goal for HbA1c
analyses is a CV of less than 3%.
8-13
While there is little
specific published information on desirable performance
standards for point-of-care HbA1c analysis, it is a generally
accepted principle that analytical performance goals for
point-of-care testing should be close or equivalent to those
used for laboratories. In the most recently completed
QAAMS testing cycle (Cycle 7), the point-of-care DCA 2000
analysers in the QAAMS program achieved a median CV of
3.4%, with 43% of QAAMS sites attaining the desired 
precision goal of less than 3% during this cycle. Whilst
acknowledging that the point-of-care DCA 2000 analyser
cannot achieve the performance base of state-of-the-art 
laboratory HPLC technology, the DCA 2000 is 
unquestionably the most practical and robust HbA1c analyser
for use in rural and remote Australia where access to 
laboratory services is often very limited or non-existent.
Other Management Services 
A total of 419 calls were received by the QAAMS help 
hotline over the past three and a half years, 49% of which
were taken during the first year of the program as teething
problems and issues of process were being addressed. In
addition to incoming calls, the QAAMS Program Manager
provided on-going advice and follow-up action for sites
whose DCA 2000 machines exhibited poorer performance.
1235 Bayer HbA1c quality control results were returned to the
QAAMS reporting office across the three and a half years of
the program. As up to seven different lot numbers of Bayer
quality control material were being used by QAAMS 
participants at any one time, it has not been possible to 
conduct detailed statistical analysis of Bayer quality control
results. In the most recent cycle of testing, 95% of all Bayer
quality control results returned were within the acceptable
limits for the particular lot number of control tested (with the
limits of acceptability the same as those used for the testing
of QAAMS samples). During 2003/4, a single lot number of
Bayer HbA1c control will be sourced for use in the program.
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Figure 3. Precision achieved by QAAMS participants and
laboratory users of the DCA 2000 across the past seven 
testing cycles.
Medicare Rebate for HbA1c Testing
In December 2000 Australia's Federal Health Minister
announced that a rebate could be claimed under the 
government's Medical Benefits Schedule (MBS) for HbA1c
tests conducted on the DCA 2000 in Aboriginal Community
Controlled Health Services. Provision of this rebate has 
facilitated the program's integration into mainstream
Aboriginal health care by ensuring there was a long-term 
sustainable funding mechanism for the program. The rebate
remains conditional on services continuing to participate in
the QAAMS program. 
Field Usage of HbA1c Testing
The charter of the QAAMS Program has been to provide 
education, training and quality management services to 
support community HbA1c testing rather than to collect or
analyse patient data, which remains the property of the 
participating services. However, participant discussion at
QAAMS workshops has revealed HbA1c testing is being 
carried out in a variety of different community settings.
These include the diabetic clinic (with some services 
establishing new diabetic clinics as a result of being able to
perform the test on-site), opportunistic testing in the health
service, home visits for patients with diabetes who are unable
to attend clinics, community functions and health promotion
activities, and field visits to outstations and distant 
communities serviced by health services. 
Further, data collected independently by NACCHO in the
first 18 months of the program indicated 2315 Aboriginal
people with diabetes were monitored using the DCA 2000
during this period.
14
Subsequently data derived from reagent
consumption figures indicate approximately 3000 HbA1c tests
were performed in each of the second and third years of the
program.
Discussion
Significant advances in medical technology over the past
decade have seen the development of point-of-care 
instruments such as the DCA 2000 that can perform tests for
the early detection and management of chronic diseases in
the community. Apart from advantages such as portability
and small sample size, the DCA 2000 has other advantages
that make it particularly applicable to the Aboriginal health
care setting.
15
Through appropriate training, Aboriginal
Health Workers can perform HbA1c tests, thereby 
empowering them to take greater responsibility for the health
of their own community members. By conducting the tests
on-site, ownership and control of health information remains
with the community, a factor crucial to the acceptance and
success of Indigenous health programs. Immediate 
availability of a result means that the Aboriginal patient with
diabetes does not have to return for a follow-up visit. 
The usefulness of the DCA 2000 machine for the early 
detection of renal disease in a single remote Aboriginal 
community has been previously demonstrated.
15-17
However,
the QAAMS program represents the first time the DCA 2000
instrument has been used in a multi-centred, nation-wide 
program for monitoring control of diabetes in Aboriginal
people. 
In March 2001 NACCHO released an independent 
evaluation on the first 18 months of the QAAMS program.
14
The executive summary of this report viewed the use of the
DCA 2000 point-of-care technology as a major opportunity
to better care for and manage Aboriginal clients with diabetes
within the community setting. It stated that the ability of the
point-of-care technology to generate rapid results served as a
catalyst to enhance patient self-management, while simplicity
of use led to high levels of acceptance by Aboriginal Health
Workers nationally. It concluded that the sense of community
control was enhanced as a result of management of diabetes
becoming more focussed within Aboriginal medical services.
Participation rate and all key performance indicators 
measured in the QAAMS program have remained constant
across the program's three-and-a half year duration. Tight
precision for HbA1c measurements in patients with diabetes is
particularly important because clinicians monitor serial
measurements across time and adjust treatment according to
changes in control of diabetes. If the analytical imprecision
of the HbA1c method is too wide, it may mask a clinically 
significant change in control of diabetes. With appropriate
education, training and on-going support, Aboriginal Health
Workers have shown they can consistently achieve a level of
analytical precision for HbA1c testing using the DCA 2000
point-of-care analyser that is equivalent to that of laboratory
scientists and technicians using the same instrument. Further,
the analytical performance base achieved by QAAMS 
participants using point-of-care technology is close to current
internationally recommended precision goals for HbA1c. We
believe this is reflective of the program’s intensive on-going
commitment to continuing education, training and support
for the participating services. Given the geographic isolation
of many Aboriginal health services and their often poor
access to laboratory services, the point-of-care DCA 2000
clearly represents the most practical and culturally 
appropriate option for community-based on-site HbA1c
measurements on Aboriginal patients with diabetes.
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The greatest challenge to the sustainability of the QAAMS
program is Aboriginal Health Worker turnover in 
participating sites and the provision of education and training
for new health workers who come into the program from
those sites. Since the program's inception in June 1999, 33
services now have a different health worker responsible for
the QAAMS program; in 10 of these services there have been
more than one health worker change across this period. It is
a remarkable testament to the goodwill and vision of the 
participating services and to the dedication and commitment
of the Aboriginal Health Workers concerned that the 
program's major performance indicators have remained 
stable across this period in spite of such change. The
QAAMS workshop provides at least one opportunity for 
formal training in a group environment every year. 
The QAAMS HbA1c model, based on education, training,
quality assurance and on-going quality management support
services, provides a sound framework for the appropriate and
sustainable use of point-of-care technology outside the 
laboratory environment. The model can be readily adapted
and is transferable to both Indigenous communities in other
parts of the world and to other point-of-care instruments and
tests. In 2003 an international participant from the Western
Pacific has joined the QAAMS HbA1c program. With further
Government support, a new QAAMS program for the 
measurement of urine albumin:creatinine ratio on the DCA
2000 commenced in February 2003, thereby maximising the
analytical capabilities of this point-of-care analyser and 
facilitating further on-site management for Aboriginal people
with diabetes. 
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